Introduction: The most common cancer is Breast Cancer and the first principal purpose of cancer deaths in females of 44-40 ages. The currency of three negative breast cancer involves 10-17%. his sort cancer of the breast is described by a negative receptor of estrogen, progesterone, and HER2 that is much more competitive than the other kinds and the forecast is weaker. Therefore, this research ...

Objective: The To distinguish between basal and non-basal subtypes of triple-negative breast cancers based on epidermal growth factor receptor cytokeratin 5/6, to establish the association diagnosis with clinicopathological parameters survival rates.Methods: retrospective study was conducted at Clinical Oncology Nuclear Medicine Department Kafrelsheikh University Hospital Tanta Hospital, Egypt,...

There has been a major need to better understand the biological characteristics of triple-negative breast cancers. Compared with estrogen receptor (ER)-positive cancers, several magnetic resonance (MR) imaging findings have been reported as characteristic findings. However, information regarding their location has not been described. Our study was to compare the location of triple-negative brea...

Parity associated breast cancer (PABC) often diagnosed within the 2-5 years after a full term pregnancy. PABC is usually present with more advanced, poorly differentiated, high-grade cancers that show shorter time to progression and often of the triple negative breast cancer (TNBC) subtype. Data from around the world show that pregnancy-associated TNBC is independently associated with poor surv...

although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue. sarcomas represent less than 1% of primary breast neoplasms. these tumors are at high risk of recurrence and are known to have poor prognosis. surgical resection is the primary treatment for these lesions and axillary lymph node dissection is not r...

Triple-negative breast cancer does not express estrogen and progesterone receptors and there is no overexpression/amplification of the HER2-neu gene. Therefore, this subtype of breast cancer lacks the benefits of specific therapies which target these receptors. About 60% of all human breast cancers express receptors for luteinizing hormone releasing hormone (LHRH, GnRH), which might be used as ...

Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this re...

BACKGROUND AND AIM We investigated the prognostic importance of dickkopf-1(DKK1) and beta-catenin expression in triple negative breast cancers. METHODS The expression of DKK1 and beta-catenin was evaluated in breast cell lines using RT-PCR and western blot. Immunohistochemistry was used to characterize the expression pattern of DKK1 and beta-catenin in 85 triple negative breast cancers and pr...

Triple negative breast cancers constitute approximately 15-20% of all breast cancers and they are more aggressive compared to other phenotypes (e.g. Luminals A and B and Her2+). Additionally, triple negative breast cancers are harder to treat because of the absence of targets for hormonal therapies such as ER, PR, and Her2+. Presently, there are only limited neoadjuvant therapy regimens availab...

Background: Previous data have shown the tumorigenicity roles of HDAC8 in breast cancer. More recently, the oncogenic effects of this molecule have been revealed in TNBC. The present study aimed to determine the diagnostic value of HDAC8 for the differentiation of TNBC from nTNBC tumors. Methods: A total of 50 cancerous and normal adjacent tumor specimens were obtained, and the clinical and pat...